)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
IDEAYA Biosciences
IDEAYA Biosciences (IDYA) investor relations material
IDEAYA Biosciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic focus, vision, and clinical pipeline
Focus on precision oncology with first- and best-in-class programs targeting solid tumors, rare aggressive cancers, and significant unmet needs.
Four clinical pipeline areas: darovasertib, ADCs/DNA damage repair, MTAP deletion, and tumor heterogeneity, with nine clinical-stage molecules and six internally discovered assets.
Utilizes predictive biomarkers, AI-driven drug discovery, and rational combinations, integrating CRISPR, chemigenomics, and computational design.
Focus on neoadjuvant/adjuvant indications, 1L metastatic disease, and synthetic lethality pathways.
Commercial strategy leverages oral administration, rapid market entry, and learnings from prior launches.
Key clinical data and trial updates
Darovasertib in metastatic uveal melanoma showed a 35% response rate, median duration of nine months, PFS of seven months, and OS over 21 months; top-line results are imminent.
Darovasertib + crizotinib achieved a 34.1% ORR and 90.2% DCR in mUM, with median OS of 21.1 months.
IDE849 (DLL3 ADC) demonstrated up to 80% ORR and 100% DCR in SCLC Phase 1, with PFS over six months.
IDE397 + Trodelvy in MTAP-deleted urothelial cancer achieved up to 57% ORR at higher dose levels.
Received FDA Breakthrough Therapy Designation for darovasertib in neoadjuvant UM; over half of patients avoided enucleation and gained significant vision.
Combination strategies and innovation
Strong focus on combination therapies, especially with DNA damage repair agents like PARG inhibitor IDE161, to enhance ADC durability.
Preclinical and in vivo data support PARG inhibition with TOPO-ADCs, showing enhanced efficacy.
IDE849 and bispecific ADCs are being advanced for SCLC and neuroendocrine tumors, with plans for registrational studies and combination trials.
IDE034, a bispecific B7H3 PTK7 ADC, shows superior efficacy versus mono-TOPO-ADCs in preclinical models.
Systemic combination approaches offer dosing flexibility compared to fixed dual payload ADCs.
Darovasertib: How to avoid Kemtrak's market issues?
Systemic DDR vs. dual payload ADC advantages?
IDE397 + Trodelvy: Durability and go/no-go criteria
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next IDEAYA Biosciences earnings date
Q4 202513 Feb, 2026
IDEAYA Biosciences
Next IDEAYA Biosciences earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
IDEAYA Biosciences Inc. is a clinical-stage biotechnology firm primarily engaged in the discovery and development of precision medicine therapeutics for cancer patients. The company's research focuses on synthetic lethality, an innovative class of precision medicine targets, aiming to produce therapeutics that are first-in-class and/or best-in-class. IDEAYA Biosciences leverages molecular diagnostics to select patient populations for its targeted therapies, emphasizing an integrated approach to the discovery and development of biomarkers and therapeutics. This approach spans early discovery through clinical development, targeting unmet needs in cancer treatment. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage